FAQ on Tonix Pharmaceuticals' TNX-801 Mpox Vaccine Presentation at Vaccine Congress 2025

What is TNX-801?

TNX-801 is a recombinant horsepox virus live vaccine candidate developed by Tonix Pharmaceuticals, showing protective efficacy against mpox and other orthopoxviruses in animal models after a single dose.

Why is the presentation of TNX-801 data significant?

The presentation is significant because it showcases the vaccine’s potential to induce durable immune responses against mpox and other orthopoxviruses, with plans to expand its use to other emerging viral threats.

Who will present the TNX-801 data at the Vaccine Congress 2025?

Dr. Sina Bavari, Executive Vice President of Infectious Disease Research and Development at Tonix Pharmaceuticals, will present the new preclinical data on TNX-801.

When and where will the TNX-801 data be presented?

The data will be presented on July 10 at the Vaccine Congress 2025 in Vienna.

What are the next steps for TNX-801 after the presentation?

Following the presentation, Tonix Pharmaceuticals plans to initiate clinical trials for TNX-801, based on the safety, immunogenicity, and efficacy findings from preclinical studies.

How does TNX-801 compare to other vaccines for mpox?

The content does not provide a direct comparison to other mpox vaccines but highlights TNX-801’s design to induce durable immune responses and its potential applicability against other emerging viral threats.

Where can I find more information about Tonix Pharmaceuticals and TNX-801?

More information can be found on Tonix Pharmaceuticals’ website at www.TonixPharma.com or in the company’s newsroom at https://ibn.fm/TNXP.

What other products is Tonix Pharmaceuticals developing?

Tonix Pharmaceuticals is developing TNX-102 SL for fibromyalgia and acute stress reaction, TNX-1300 for cocaine intoxication, TNX-1500 for organ transplant rejection and autoimmune diseases, and TNX-4200 as a broad-spectrum antiviral agent, among others.